Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Perhaps the "analysts" and their friends have loaded up now. I'm expecting them to issue their new expert estimates soon:
https://www.marketwatch.com/investing/stock/adms/analystestimates?mod=mw_quote_tab
i got caught up in those Halts. Chased only to see it get sold down.
such good news, doesnt really make sense
approval and only %30 up
with low ss ?
I bid for Feb and Mar 7.5 calls for 3 straight weeks in mid-January since I wanted as little time-value as possible. My average % gain is ~4300%. I closed ~19% of my calls last Friday to get my initial outlay back, since the news could have been neutral/bad, and released pre/post market.
Trading Halt
02/01/2021 13:00:14 ADMS Adamas Pharmaceuticals, Inc Cm NASDAQ T1
T1 Halt - News Pending
Trading is halted pending the release of material news.
8-K: 2/1/21
Item 1.01 Entry Into a Material Definitive Agreement.
As previously disclosed, Adamas Pharma, LLC, a wholly-owned subsidiary of Adamas Pharmaceuticals, Inc. (the “Company”) is involved in a lawsuit against Zydus Worldwide DMCC and Zydus Pharmaceuticals (USA), Inc. (collectively “Zydus”) in the United States District Court for the District of New Jersey alleging infringement of the Company’s patents by Zydus. On January 30, 2021, the Company entered into a definitive agreement (the “Definitive Agreement”) with Zydus pursuant to which the parties agreed to end the lawsuit and dismiss it without prejudice. Pursuant to the Definitive Agreement, the Company grants a license to make, use, sell, offer to sell and import a generic version of GOCOVRI® (amantadine) extended release capsules, effective as of March 4, 2030, or earlier in certain circumstances typical for such agreements. In addition, the Definitive Agreement contains provisions that may accelerate the license date, including if unit sales of GOCOVRI in the 12-month period ending July 31, 2025 or any subsequent 12-month period decline by a specified percentage below GOCOVRI unit sales in the year ended December 31, 2019.
The Definitive Agreement will be submitted to the U.S. Federal Trade Commission and the U.S. Department of Justice. The Company expects to file the Definitive Agreement as an exhibit to its Quarterly Report on Form 10-Q for the quarter ending March 31, 2021.
Zydus Pharmaceuticals
Letting go of a small % of my ADMS calls, into the close, to cover initial outlay.
Calls are popping in the microwave...
ADMS: ~71% of ~29M OS held by insiders/funds. This implies only ~8M of the ~19M float is tradable, provided the funds hang on.
Looks like someone has noticed ADMS. Now just need pps over $7.50 for Feb. Calls...
(i) 2021-02-01
ADMS GOCOVRI (ADS-5102)
FDA Approval announced August 24, 2017. PDUFA date February 1, 2021 for sNDA to include treatment of OFF episodes in PD patients receiving levodopa.
(ii) revenue update
$ADMS | #AdamasPharmaceuticals Upside Targets
Adamas Pharmaceuticals , Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.
* * $ADMS Video Chart 08-07-2020 * *
Link to Video - click here to watch the technical chart video
Hey, remember when this was about to launch and the VP of Market Access, M. Masterson, was considered to be “the most innovative person in Market Access?” LOLOLOLOLOL
Wow, nice swing and miss.
Took a small position for 1000 shares on this, will likely hit $10 tomorrow plenty of cash on hand and news after hours.
* * $ADMS Video Chart 01-08-2020 * *
Link to Video - click here to watch the technical chart video
* * $ADMS Video Chart 12-18-2019 * *
Link to Video - click here to watch the technical chart video
* * $ADMS Video Chart 12-17-2019 * *
Link to Video - click here to watch the technical chart video
* * $ADMS Video Chart 11-08-19 * *
Link to Video - click here to watch the technical chart video
LOLOLOLOL!!!
At $130k a year, this extended release of an ages old drug prices itself out of any success.
Who the hell came up with the price?!? Hopefully the we’re terminated.
load up before monster news hit the wire
phase 3 results imminent
trading massive under cash
news coming
* * $ADMS Video Chart 10-04-2019 * *
Link to Video - click here to watch the technical chart video
* * $ADMS Video Chart 09-30-2019 * *
Link to Video - click here to watch the technical chart video
* * $ADMS Video Chart 09-20-2019 * *
Link to Video - click here to watch the technical chart video
News: $ADMS ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, May 31, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. (“Adamas” or “the Company”) (NASDAQ: ADMS ) f...
Find out more https://marketwirenews.com/news-releases/ongoing-investigation-alert-the-schall-law-firm-announces-it-is-investigating-claims-against-adamas-pharmaceuticals-inc-and-encourages-investors-with-losses-in-excess-of-100-000-to-contact-the-firm-8278320.html
This is a garbage company with garbage leadership and a garbage product. People are resigning daily. Failed experiment. Look for $5 soon. It’s been a great Puts play.
very interesting. fundamentals + technicals. sitting on starter today.
Is anyone here??? Looks like a sign of life today, in AM anyway. When it moves it moves quickly due to the heavy ownership of tutes thereby little float available. We just need a couple of big boys to come in here. SP can easily go to $17 to 18 range where it should be right now. it has stepped down way too much. turn around seems to have begun.
How may this affect ADMS?
https://finance.yahoo.com/news/acorda-files-parkinson-apos-drug-140002308.html
Looks like a long waiting game.
How much do u like HGMT. Hearing calls for 15.
Looking good here compared to the rest of the market.
I’m thinking soon. They just raised 85 million in a day at 41.50
Followers
|
11
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
118
|
Created
|
12/24/14
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |